Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Bausch + Lomb Post-Surgery Eye Pain Drug Misses Study Goal But Shows Early Relief

Bausch + Lomb Corporation (NYSE:BLCO) on Thursday reported topline Phase 2 results showing its topical eye drop BL1332 missed its primary pain-reduction endpoint after photorefractive keratectomy (PRK) surgery. PRK is a flapless laser eye surgery that reshapes the cornea to correct myopia (nearsightedness), hyperopia (farsightedness), and astigmatism. The data showed it delivered consistent…

Bausch + Lomb Post-Surgery Eye Pain Drug Misses Study Goal But Shows Early Relief

We haven't written up this one. Benzinga has the full story — the link below goes straight to it.

Read the original at benzinga.com →

More in Health & Medicine

More from Friday 20 November →